Stockfleth E, Meyer T, Benninghoff B, Christophers E
Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, D-24105 Kiel, Germany.
Br J Dermatol. 2001 May;144(5):1050-3. doi: 10.1046/j.1365-2133.2001.04197.x.
Actinic keratoses (AK) are premalignant lesions, which are routinely treated by destructive procedures such as cryotherapy, electrodessication or topical 5-fluorouracil.
The aim of this study is to report six cases of AK treated with a potential new topical therapy, imiquimod.
Subjects included in this study had suffered with recurrent AK for between 5 and 16 years. All six men were treated with imiquimod 5% cream three times a week for 6-8 weeks. In the event of a local skin reaction treatment was modified to two times per week.
All the AK lesions were successfully cleared after treatment with imiquimod cream 5% for 6-8 weeks. Histologically, no apparent signs of persisting AK could be detected, and no recurrences were reported during follow up.
This study suggests that imiquimod may be useful as a new therapy for the treatment of actinic keratoses.
光化性角化病（AK）是癌前病变，通常通过冷冻疗法、电干燥法或外用5-氟尿嘧啶等破坏性方法进行治疗。
本研究旨在报告6例采用一种潜在的新型局部治疗药物咪喹莫特治疗的光化性角化病病例。
本研究纳入的受试者患有复发性光化性角化病5至16年。所有6名男性患者均接受5%咪喹莫特乳膏治疗，每周3次，持续6至8周。若出现局部皮肤反应，则将治疗调整为每周2次。
所有光化性角化病皮损在接受5%咪喹莫特乳膏治疗6至8周后均成功清除。组织学检查显示，未检测到光化性角化病持续存在的明显迹象，随访期间未报告复发情况。
本研究表明，咪喹莫特可能作为一种治疗光化性角化病的新疗法。
